🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million infections annually. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts believe that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization represents a significant shift in the management of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to results published in a prominent scientific publication, the new drug successfully treated more than 90% of cases of the STI. This places it at an comparable level with the current standard treatment, which uses an injection and a pill. The study enrolled nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Clinicians on the front lines have expressed positive views. The availability of a one-pill regimen like this is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.